the amyloid form of a peptide derived from prostatic acid phosphatase, PAP248-286 (known as the semen-derived enhancer of virus infection or SEVI), has been reported to increase the rate of HIV infection by up to 400,000-fold, making this naturally abundant amyloid species a particularly attractive target for development of molecules that can reduce the spread of HIV.
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Previously, we reported that monomeric and oligomeric amyloid-targeting 6-methylbenzothiazole aniline (BTA) compounds could form protein-resistive coatings 15À19 on amyloids and could inhibit SEVI-mediated HIV infection. 20, 21 We showed that while the monomeric BTA molecules were effective at inhibiting HIV infection, oligomeric versions of BTA exhibited improved activity for inhibiting SEVI-mediated HIV infection. These BTA Interestingly, while the binding of the BTA oligomers to SEVI dramatically increased compared to a monomeric BTA analogue (e.g., by 590-fold in the case of a BTA pentamer), the improvement in the functional activity of these oligomers to reduce HIV infection was considerably less pronounced (e.g., by only 65-fold in the case of a BTA pentamer). From these previous results, we hypothesized that the improved effect of the BTA oligomers on reducing SEVI-mediated HIV infection could be a result of the increased size of the BTA oligomers compared to BTA monomers rather than their improved binding to SEVI. In order to test this hypothesis, here we investigated the effect of polymeric nanoparticles (NPs) containing covalently attached amyloid-binding compounds on SEVI-enhanced HIV infection ( Figure 1 ). We designed these polymeric NPs to be approximately the same size as HIV virions 22 (∼150 nm) to assess the effect of steric interferences on the reduction of SEVI enhanced HIV infection by an amyloid-binding agent. We found that these polymeric NPs had greatly (over 200-fold) increased potency in inhibiting SEVI-enhanced HIV infection in cells despite retaining similar (or slightly lower) binding properties to SEVI compared to an amyloid-binding monomer. The effects of these NPs on reduction of SEVI-mediated HIV infection were greater than the activity found for amyloid-binding oligomers with much stronger avidity. The results suggest that consideration of steric bulk in the design of SEVI-binding molecules could be an important factor along with thermodynamic binding for neutralizing the effects of natural, aggregated amyloid proteins on sexual transmission of HIV.
RESULTS AND DISCUSSION
Design, Synthesis, and Characterization of Polyacrylate-Based Polymers. Prior work has shown that polyacrylamidebased polymers carrying sialic acid groups could bind to influenza virus particles and effectively inhibit the direct binding of the virus to cells through steric inhibition. 23 Inspired by these previous studies, we hypothesized that amyloid-binding polymers or polymeric nanoparticles could create a significant steric barrier to block interactions between SEVI and HIV virions and, thus, effectively inhibit SEVI-mediated HIV infection. Here, we synthesized polyacrylate-based polymers carrying amyloid-binding BTA moieties. We chose to use polyacrylate-based polymers because they are nontoxic and synthetically accessible in useful quantities. Polyacrylate polymers are also known to form spherical nanoparticles of 100À200 nm in diameter, 24, 25 which is approximately the same size as HIV virions. 22 Moreover, their capability to form nanoparticles of relatively narrow dispersity makes it possible to more accurately assess efficacy for reducing HIV infection compared to a mixture of polymers with large variability in size, shape, and aggregation state.
To develop a polyacrylate-based polymer carrying amyloid-binding BTA moieties, we synthesized an analogue of BTA-EG 6 (1, Figure 2 ) 16, 19 comprising an acrylate group (2) . This BTA-acrylate monomer 2 was then subjected to free-radical conditions 26, 27 at Figure 2 ). Analysis of polymer 3 by static light scatteringÀmultiangle light scattering (SLSÀMALS) revealed that this polymer had a number-average molecular weight (M n ) of 68K, with a polydispersity index (PDI) of 1.63 (Table 1) . Examination of polymer 3 by 1 H NMR suggested that 56% of the residues in the polymer contained BTA groups.
As a control, we also synthesized polyacrylatebased polymer 5 ( Figure 2 ) containing hexaethylene glycol groups but lacking the BTA moieties. This control polymer was designed to test whether amyloid-binding groups are necessary for reducing SEVI-mediated HIV infection. While this control polymer had a lower M n and M w than 3, it had a similar PDI as the BTAcontaining polyacrylate-based polymer 3 ( Table 1) .
Generation and Characterization of Polymeric Nanoparticles. The BTA-containing polyacrylate polymer 3 is substantially larger than the previously reported oligomers of BTA 21 and, thus, was expected to be useful to probe the effects of sterics on reducing SEVI-mediated HIV infection. However, the hydrophobic nature of 3 makes this polymer highly prone to uncontrolled aggregation in aqueous solutions. Formulation of polymer 3 into nanoparticles was, therefore, pursued with the goal of significantly narrowing the size and shape dispersity of aggregates, thereby making it easier to quantitatively assess the activity of these polymers in SEVImediated HIV infectivity assays. In order to convert polymer 3 into nanoparticles, we used a previously reported solvent evaporation method 28, 29 to generate spherical nanoparticles with average diameters of ∼200 nm (PD = 0.19, see Figure S1 in the Supporting Information), as determined by dynamic light scattering (DLS). Analysis of these nanoparticles by cryo-electron microscopy (cryo-EM, Figure 3A ) suggested a smaller average diameter of the spherical nanoparticles of 83 nm. Since larger particles tend to scatter more light than smaller particles, estimations of size of nanoparticles by DLS will often reflect a greater weight given to larger particles that may be present in the sample even if they represent only a minor fraction of particles. 30 Thus, we consider the estimation of nanoparticle diameter obtained from cryo-EM images as a more accurate method to determine the average size of nanoparticles in the sample. Regardless of the discrepancy in size of the nanoparticles as estimated by DLS or cryo-EM, spherical polymeric nanoparticles with diameters between 83 and 200 nm are of similar shape and size as HIV virions. 22 We expected that nanoparticles in this size range should be large enough to impart significant steric interactions between virus particles and SEVI amyloid fibrils. When we incubated these particles with a solution of SEVI fibrils ( Figure 3B ), unstained transmission electron microscopy (TEM) images revealed a population of nanosized objects that were consistent with SEVI fibrils coated with nanoparticles ( Figure 3C ). The nanosized objects shown in Figure 3C were not present in samples containing nanoparticles ( Figure 3A ) or SEVI fibrils ( Figure 3B ) alone. These results from imaging, therefore, support that nanoparticles derived from polymer 3 can bind and coat SEVI fibrils and, thus, may be capable of sterically inhibiting interactions between SEVI and HIV virions.
Lastly, we evaluated the stability of the polymeric nanoparticles derived from polymer 3 by DLS. When incubated at 25 or 37°C in deionized water, we 1832 observed a slight decrease (<10%) in the average size of the particles over the first 6 h (at either temperature).
Over a 48 h period, we observed a decrease in average particle size by ∼18% at 25°C and ∼23% at 37°C (see Figure S2 in the Supporting Information). The polydispersity (PD) of the nanoparticles, however, remained unchanged at either temperature over the 2-day period. For comparison, polymeric nanoparticles with poor stability have been characterized with large observed changes in size (by >30%) and PD (by >10-fold) over a period of less than a few hours. 31 Given that SEVI-mediated HIV infection in cells takes place within a 2 h period, 20,21 the nanoparticles derived from polymer 3 appear to have suitable stability for evaluation in infectivity assays.
Binding Studies of BTA-Containing Polyacrylate Polymer 3 and Control Polymer 5 with SEVI Fibrils. We quantified the interaction of polymer 3 and SEVI fibrils using a previously reported centrifugation method. 20, 21 This assay revealed that polymer 3 bound to SEVI amyloid fibrils with an apparent K d = 14 μg/mL (Table 1 and see Figure S3 in the Supporting Information). If we use the number-average molecular weight (M n ) as an estimate of the molecular weight (MW) of the polymer, the apparent K d value is ∼0.21 μM. For comparison, the reported K d value for the binding of BTA-EG 6 to SEVI fibrils is 0.127 μM 20 (see also Table 2 ). We attribute this slightly weaker apparent K d for polymer binding to SEVI compared to monomer to the likely possibility that the majority of the amyloid-binding BTA moieties are buried within the hydrophobic bulk of the polymer rather than remaining accessible to the aqueous environment and available for binding to an amyloid surface. While we expect nanoparticles to exhibit an apparent binding to SEVI that would be similar to polymer 3, the centrifugation assay used in these studies could not be applied to measure apparent binding constants for the nanoparticles due to the colloidal nature of the nanoparticle suspensions (which results in pelleting of the nanoparticles upon centrifugation when either bound or unbound to SEVI). In order to evaluate whether control polymer 5 (which lacks fluorescent amyloid-binding groups) exhibits any significant nonspecific binding to SEVI, we performed a competition assay where we incubated a constant concentration of 100 μg/mL of polymer 3 and 10 μg of SEVI amyloid fibrils in water in the presence of increasing concentrations of control polymer 5. This competition assay made it possible to evaluate the binding between polymer 5 and SEVI by measuring the decrease in the fluorescence of polymer 3 if competitively displaced from the SEVI surface. 20, 21 As expected, the results show that polymer 5 does not exhibit any significant binding to SEVI at concentrations e1 mg/mL (i.e., at concentrations that were 10-fold higher than polymer 3; see Figure S4 in the Supporting Information). BTA-Containing Polymeric Nanoparticles Effectively Inhibit SEVI-Mediated HIV Infection. We measured the half-maximal inhibitory concentration (IC 50 ) of HIV infectivity with and without the presence of SEVI amyloid fibrils for our polyacrylate polymer 3 and our polymeric nanoparticles using a luciferase reporter cell line (TZM-bl cells 21 ) that was exposed to infectious HIV IIIB . For BTA-containing polyacrylate polymer 3, we found an IC 50 value of ∼14 μg/mL ( Figure 4A ,B) for inhibition of SEVIenhanced HIV infection. This IC 50 value corresponds to a concentration of ∼200 nM polymer, which is similar in activity to the previously reported most potent amyloid-targeting BTA-pentamer 6 21 ( Figure 5 ) for inhibiting SEVI-mediated infection of HIV. Additionally, polymer 3 was significantly more active on a per mole basis in this infection assay compared to BTA-EG 6 1.
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When we consider the activity of polymer 3 on a per BTA basis (IC 50 = 23 μM), however, the polymers appeared to have activity similar to that of BTA-EG 6 1 (IC 50 = 13 μM). This lower than expected apparent activity for polymer 3 on a per BTA basis may be due to the heterogeneity of polymer aggregates that are likely formed in solution, resulting in a mixture of species with varying activity for binding to SEVI (and subsequent inhibition of SEVI-mediated HIV infection).
Interestingly, the BTA-containing polymeric nanoparticles exhibited an IC 50 value of ∼4 μg/mL (Figure 4  C,D) , which corresponded to a concentration of 59 nM polymer. While the molar activity for these nanoparticles is the most active of any SEVI-binding species reported to date for reducing SEVI-enhanced HIV infection, the activity of these nanoparticles on a per BTA basis (IC 50 = 6 μM) is also twice as active as BTA-EG 6 20 and over three times more active than polymer 3.
We attribute the increased activity of these nanoparticles relative to polymer 3 to the increased uniformity of shape and size of the nanoparticles compared to a complex mixture of aggregates that likely form with The control polymer 5 was, as expected, completely ineffective at inhibiting SEVI-mediated HIV infection at concentrations below 40 μg/mL (∼2 μM), emphasizing the importance of an amyloid-binding moiety on the polymer or nanoparticle for activity ( Figure 4E ). In order to rule out that the observed activity of the polymers and nanoparticles reported here could be affected by unexpected toxicity of these materials to cells, we exposed ectocervical cells to high concentrations of 3, 5, and the BTA-containing polymeric nanoparticles for 24 h and measured cell viability using an Alamar Blue assay. 20 We found that none of the polymers or nanoparticles displayed significant toxicity at concentrations below 40 μg/mL ( Figure 4F ). In order to evaluate the effect of sterics of SEVIbinding molecules on reduction of SEVI-mediated HIV infection, we compared the 
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SEVI-mediated HIV infection that is at least 100-fold higher than the concentration required for binding to the amyloid surface. These observations suggest that steric bulk on the amyloid-binding agent greatly improves efficiency for inhibiting SEVI-mediated HIV infection.
CONCLUSION
In conclusion, we developed a polymer comprising amyloid-binding BTA moieties that maintained good affinity for SEVI amyloid fibrils. Nanoparticles generated from this polymer were similar in size and shape to HIV virions and effectively inhibited SEVImediated infectivity of HIV in cells. These polymers and nanoparticles were much more efficient at inhibiting SEVI-enhanced HIV infection compared to previously reported monomeric and pentameric versions of BTA, suggesting that steric hindrance can play a significant role in the design of effective SEVI neutralizing agents. These results further support the use of amyloid-targeting agents as prophylactic microbicide supplements for reducing HIV transmission through sexual contact. Since polymeric nanoparticles can be used as vehicles for controlled delivery of a variety of drugs, 29, 32, 33 the results reported here pave the way for development of multifunctional polymeric materials that can be targeted to amyloids associated with HIV transmission and possibly other diseases. 
METHODS
Synthesis of BTA-EG 6 -acrylate (2) . In a flame-dried round-bottom flask purged with N 2 , BTA-EG 6 1 16 (500 mg, 0.99 mmol) was dissolved in 25 mL of dichloromethane (DCM). The reaction mixture was cooled to À78°C in a dry ice bath (acetone/CO 2 ), and triethylamine was added (138 μL, 0.99 mmol) over 5 min. After incubation for an additional 5 min, a solution of acryloyl chloride (67 μL, 0.83 mmol) in DCM (1 mL) was added dropwise. After being warmed to room temperature (rt) over 24 h, the reaction mixture was concentrated to dryness and purified via silica gel chromatography using ethyl acetate (EtOAc) as the eluent. The product was dried under vacuum to afford an orange oil (334 mg, 72% yield). 3). Acrylic acid (32 μL, 0.47 mmol), 2 (263 mg, 0.47 mmol), and AIBN (4 mg, 0.024 mmol) were dissolved in butyl acetate (1 mL). The reaction mixture was degassed by gently bubbling dry N 2 gas with stirring for 30 min. After degassing, the reaction vial was sealed under N 2 atmosphere and placed in an oil bath at 65°C for 16 h. After being cooled to rt, the cloudy solution was placed in a 50 mL conical vial. The reaction vial was rinsed with DCM (2 mL) and added to the conical vial. The polymer was precipitated by addition of hexanes (30 mL), and the solution was decanted. The polymer was redissolved in DCM and again precipitated with hexanes. The product was dried under vacuum to afford a yellow solid (100 mg, 34% yield). 69 (2H, bs) . Integration of aromatic protons in the region δ 6.62À7.82 ppm was used to determine incorporation of monomer 2 (see the Supporting Information for details).
Synthesis of Hexaethylene Glycol Monomethyl Ether Acrylate (4). In a flame-dried round-bottom flask purged with N 2 was dissolved hexaethylene glycol monomethyl ether (304 mg, 1.03 mmol) in DCM (5 mL). The reaction mixture was cooled to À78°C in a dry ice bath (acetone/CO 2 ), and triethylamine was added (172 μL, 1.23 mmol) over 5 min. After another 5 min, a solution of acryloyl chloride (100 μL, 1.23 mmol) in DCM (1 mL) was added dropwise. After being warmed to rt over 24 h, the reaction mixture was concentrated to dryness and purified via silica gel chromatography using EtOAc as the eluent. The product was dried under vacuum to afford an orange oil (200 mg, 56% yield). Synthesis of Poly(hexaethylene glycol monomethyl ether acrylate) (5). Compound 6 (180 mg, 0.51 mmol) and AIBN (2 mg, 0.013 mmol) were dissolved in butyl acetate (1 mL). The reaction mixture was degassed by gently bubbling dry N 2 gas with stirring for 30 min. After degassing, the reaction vial was sealed under N 2 atmosphere and placed in an oil bath at 65°C for 16 h. After being cooled to room temperature, the cloudy solution was placed in a 50 mL conical vial. The reaction vial was rinsed with DCM (2 mL) and added to the conical vial. The polymer was precipitated by addition of hexanes (30 mL), and the solution was decanted. The polymer was redissolved in DCM and again precipitated with hexanes. The product was dried under vacuum to afford a colorless oil. Polymer Analysis. Polymer polydispersity index (PDI) and molecular weight were determined by size-exclusion chromatography (Phenomenex Phenogel 5u 10, 1K -75K, 300 Â 7.80 mm in series with a Phenomenex Phenogel 5u 10, 10À1000 K, 300 Â 7.80 mm (0.05 M LiBr in DMF, 0.75 mL/min, 60°C)) using a Shimadzu LA-10AT pump equipped with a UV detector (Hitachi-Elite LaChrom L-2420), a multiangle light scattering detector (DAWN-HELEOS, Wyatt Technology), and a refractive index detector (Hitachi L-2490). Data analysis was performed using the ASTRA software package.
Nanoparticle Formulation. We dissolved 2 mg of polymer 3 in 2 mL of tetrahydrofuran (THF). This solution was added dropwise to an equal volume of deionized (DI) water with vigorous stirring. After the solution was stirred for 30 min, the THF was removed in vacuo and the remaining 1 mg/mL nanoparticle solution was analyzed via dynamic light scattering.
Nanoparticle Analysis by Dynamic Light Scattering. Particle size determination by dynamic light scattering was performed on a Wyatt DynaPro NanoStar (Wyatt Technology, Santa Barbara, CA) instrument using a disposable cuvette (Eppendorf UVette 220À1600 nm). Samples were analyzed using a concentration of nanoparticles of 1 mg/mL (with respect to polymer concentration) and data processed using Wyatt DYNAMICS V7 software. Data were exported for final plotting using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA), and a representative plot of signal intensity versus radius is shown in Figure S1 (Supporting Information).
Nanoparticle and SEVI Analysis by Cryo-EM. Nanoparticles were resuspended in a volume (50 μL) of water with a concentration of 20 mg/mL nanoparticle (with respect to polymer ARTICLE SHEIK ET AL.
www.acsnano.org 1835 concentration) prior to imaging. For SEVI, the amyloid fibrils were suspended at a concentration of 10 mg/mL (with respect to peptide concentration) in PBS. Small aliquots (<5 μL) of each sample were separately applied to holey grids, which had been glow discharged and plasma cleaned. These Cryo-EM samples were vitrified using liquid ethane as the cryogen. Frozen samples were transferred into a precooled cryo-transfer holder to maintain low temperature. Images acquired on a FEI Tecnai G2 Sphera operated at 200 keV using a Gatan Ultrascan 1000 UHS 4 MP CCD camera.
Preparation of SEVI Fibrils. PAP248-286 was dissolved in PBS at a concentration of 10 mg/mL. Fibrils were formed by agitation in an Eppendorf Thermomixer at 1400 rpm and 37°C for 72 h. The presence of fibrils was confirmed by a previously described Congo Red spectroscopic assay. 21, 36 TEM Imaging of SEVI Fibrils Incubated with Nanoparticles. In order to obtain TEM images of SEVI fibrils incubated with NP, a 5 μL solution of NPs (5 mg/mL) was incubated with a 2 μL solution of SEVI (2 mg/mL) in water over an air plasma oxidized EM grid. The mixture was agitated via pipet on the grid for approximately 5 min. After 5 min, excess water was wicked away using filter paper, and the dried sample was subjected to TEM imaging on a FEI Tecnai G2 Sphera using a Gatan Ultrascan 1000 UHS 4 MP CCD camera.
Measurement of the Apparent Dissociation Constant, K d , of 3 to SEVI Fibrils. The binding of polymer 3 to SEVI amyloid fibrils was estimated using a centrifugation assay described previously. 20, 21 Briefly, 200 μL of various concentrations of 3 in 5% DMSO/water were incubated in the presence or absence of 10 μg of SEVI to give a final volume of 201 μL of solution. These incubations were performed in duplicate runs and allowed to equilibrate for 12 h at room temperature. After equilibration, each solution was centrifuged at 16000g for 30 min at 4°C. The supernatants were separated from the pelleted fibrils, and 200 μL of fresh water was added to resuspend the pellets. Aliquots (100 μL) of each resuspended pellet were pipetted into a cuvette (ultramicrocuvette,10 mm light path, Hellma, Müllheim, Germany), and the fluorescence of the bound molecule was determined at 355 nm excitation and 420 nm emission using a spectrofluorometer (Photon Technology International, Inc., Birmingham, NJ). Each measurement experiment was repeated at least 3 times. Error bars represent standard deviations from the mean. The graph shown in Figure S3 (Supporting Information) shows the fluorescence intensity versus concentration of polymer 3; the data were fitted using the following one-site specific binding algorithm to determine K d : Y = B max X/(K d þ X), where X is the concentration of 3, Y is the specific binding fluorescence intensity, and B max corresponds to the apparent maximal observable fluorescence upon binding of BTA polymer to SEVI fibrils. The data were processed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA).
Evaluation of SEVI-Mediated Enhancement of HIV-1 Infectivity of TZM-bl Cells in the Presence of BTA Polymer and Nanoparticles. TZM-bl cells (in DMEM culture medium supplemented with 10% FBS, 50 units/mL penicillin, and 50 μg/mL streptomycin) were seeded on 96-well flat-bottomed tissue culture plates at a density of 4 Â 10 3 cells/well. Plates were incubated for 12 h (in a humidified atmosphere of 95% air, 5% CO2 at 37°C) to promote attachment of cells to the wells. HIV IIIB virions were then pretreated for 10 min at room temperature with 15 μg/mL SEVI fibrils in the presence or absence of polymer 3, 5, or polymeric nanoparticle. Treated virions were then added to the plated TZM-bl cells and were incubated for 2 h at 37°C. After incubation, the cells were washed with DPB, and the media was replaced. Infection was assayed after 72 h by quantifying luciferase expression with PerkinElmer Britelite Plus and measuring luminescence with a microplate reader (DTX880, Beckman Coulter). All data are represented as the mean ( standard deviation of triplicate measurements. ANOVA with Tukey's post test was employed in all analyses of data. A p-value <0.05 was considered statistically significant.
Toxicity Assay. Cervical epithelial (ectocervical) cells (3EC1 cell line) were treated for 24 h with polymer 3, polymeric nanoparticles, and polymer 5 at concentrations up to 40 μg/mL. After 24 h, cell viability was analyzed by measuring cellular metabolic activity using the resazurin cytotoxicity assay (Alamar Blue; Invitrogen), in accordance with the manufacturer's protocol. Cells were also treated with 0.1% Nonoxynol-9 as a positive control for cytotoxicity.
